Brief: Island Pharmaceuticals Announces Purchase Of Galidesivir Antiviral Program From Biocryst Pharmaceuticals
09/07/2025 02:33
July 9 (Reuters) - Island Pharmaceuticals Ltd ILA.AX: ACQUISITION OF GALIDESIVIR ANTIVIRAL PROGRAM FROM BIOCRYST PHARMACEUTICALS DEAL COMPLETED FOR BASE PURCHASE PRICE OF $550,000 Further company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026